ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Portfolio Tracker
Get an update on your stocks every day. See earnings revisions, new reports and Zacks Rank changes at a glance. Click here to learn more.

Quote:

Search for Ticker

Free Membership

Search:

ACAD: Acadia Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ACADIA PHARMACEUTICALS INC (NASD)
ACAD	1.32	-0.02	(-1.49%)	Vol. 165,388	16:00 ET

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.

General Information

ACADIA PHARMA

3911 Sorrento Valley Boulevard San Diego, CA 92121 Phone: 858 558-2871 Fax: 858 558-2872 Web: www.acadia-pharm.com Email: ir@acadia-pharm.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/08/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	1.34
52 Week High	6.60
52 Week Low	0.75
Beta	2.27
20 Day Moving Average	493,955.44
Target Price Consensus	2.83

% Price Change
4 Week	-16.88
12 Week	-77.76
YTD	47.78

% Price Change Relative to S&P 500
4 Week	-17.77
12 Week	-79.03
YTD	22.30

Share Information
Shares Outstanding (millions)	37.32
Market Capitalization (millions)	49.63
Short Ratio	0.62
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.19
Current Year EPS Consensus Estimate	-1.17
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/08/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.75
30 Days Ago	2.75
60 Days Ago	2.75
90 Days Ago	2.50

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	36.11%
vs. Previous Quarter	32.35%

Sales Growth
vs. Previous Year	763.48%
vs. Previous Quarter:	33.79%

Price Ratios
Price/Book	1.87
Price/Cash Flow	-
Price / Sales	10.02

ROE
09/30/09	-128.43
06/30/09	-120.00
03/31/09	-101.78

ROA
09/30/09	-81.72
06/30/09	-83.87
03/31/09	-84.01

Current Ratio
09/30/09	-
06/30/09	3.26
03/31/09	4.22

Quick Ratio
09/30/09	-
06/30/09	3.26
03/31/09	4.22

Operating Margin
09/30/09	-1,017.76
06/30/09	-1,970.94
03/31/09	-5,247.41

Net Margin
09/30/09	-
06/30/09	-2,045.70
03/31/09	-5,428.33

Pre-Tax Margin
09/30/09	-
06/30/09	-2,045.70
03/31/09	-5,428.33

Book Value
09/30/09	-
06/30/09	0.71
03/31/09	1.03

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	-
06/30/09	0.01
03/31/09	0.01

Debt to Capital
09/30/09	-
06/30/09	0.83
03/31/09	0.83


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research